Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

17.74 +0.05 (+0.28%)
Streaming Delayed Price Updated: 11:00 AM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hutchmed China Ltd ADR

HUTCHMED to Announce 2022 Final Results
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
From HUTCHMED (China) Limited
Via Globe NewsWire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
From Prenetics Limited
Via Globe NewsWire
Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing
Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via Globe NewsWire
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
From HUTCHMED (China) Limited
Via Globe NewsWire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022
From Virtual Investor Conferences
Via Globe NewsWire
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED (China) Limited (NASDAQ:HCM) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/08/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at HUTCHMED (China) Limited. 
Via SBWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages HUTCHMED (China) Limited Investors with Losses to Inquire About Class Action Investigation – HCM
From The Rosen Law Firm, P.A.
Via Business Wire
NASDAQ:HCM Shareholder Notice: Investigation over Possible Securities Laws Violations by HUTCHMED (China) Limited
San Diego, CA -- (SBWIRE) -- 05/16/2022 -- HUTCHMED (China) Limited is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
From Epizyme, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.